ELISA Kit for Visfatin (VF) Homo sapiens (Human) Competition ELISA

Nampt; NAmPRTase; PBEF; PBEF1; Pre-B-Cell Colony Enhancing Factor; Nicotinamide Phosphoribosyltransferase

  • Product No.CEA638Hu
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • Sample Typeserum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
  • Test MethodCompetitive Inhibition
  • Assay Length2h
  • Detection Range1.23-100ng/mL
  • SensitivityThe minimum detectable dose of this kit is typically less than 0.51ng/mL.
  • Specificity This assay has high sensitivity and excellent specificity for detection of Visfatin (VF).No significant cross-reactivity or interference between Visfatin (VF) and analogues was observed.
  • ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
  • DownloadInstruction Manual
  • UOM 48T96T 96T*5 96T*10 96T*100 Out of stock
  • FOB US$ 466.00 US$ 665.00 US$ 2,993.00 US$ 5,653.00 US$ 46,550.00
  • Quantity
  • Add to Cart Distributors
  • ELISA Kit for Visfatin (VF) Packages (Simulation)
  • ELISA Kit for Visfatin (VF) Packages (Simulation)
  • ELISA Kit for Visfatin (VF) Results demonstration
  • CEA638Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered


Matrices listed below were spiked with certain level of recombinant Visfatin (VF) and the recovery rates were calculated by comparing the measured value to the expected amount of Visfatin (VF) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 87-101 94
EDTA plasma(n=5) 94-102 99
heparin plasma(n=5) 82-93 85


Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Visfatin (VF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Visfatin (VF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%


The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Visfatin (VF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 91-101% 90-101% 86-98% 88-104%
EDTA plasma(n=5) 96-104% 89-97% 82-93% 78-92%
heparin plasma(n=5) 91-99% 79-97% 81-93% 81-92%


The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

ELISA Kit for Visfatin (VF)

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Visfatin (VF) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Visfatin (VF) and unlabeled Visfatin (VF) (Standards or samples) with the pre-coated antibody specific to Visfatin (VF). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Visfatin (VF) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Visfatin (VF) in the sample.


  • Diabetes Research and Clinical PracticeThe relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistanceScienceDirect: S0168822711002956
  • J Physiol Pharmacol. Early-effect of bariatric surgery (Scopinaro method) on intestinal hormones and adipokines in insulin resistant Wistar rat.Pubmed: 24304571
  • Endocr J.CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytesPubmed:25168658
  • Exp Ther Med.Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndromePubmed:Pmc3991522
  • Eur J Cancer Prev.Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization.Pubmed:25055182
  • GenomeVisfatin −948G/T and resistin −420C/Gpolymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseasesNrcresearchpress:Source
  • PLOS ONEAntidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting DrugPubMed: 26262991
  • Alcoholism and Drug AddictionChanges in concentration of visfatin during four weeks of inpatient treatment of alcohol dependent malesScience: Article
  • CytokineVariation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapiesPubMed: 26539806
  • GenomeGenetic Variations in Visfatin and Resistin Genes in Egyptian Type 2 Diabetic Patients With and Without ComplicationsPubMed: 25120107
  • Acta HistochemicaFavorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokinesscience:S0065128116301234

Recommend products